Karyopharm Therapeutics Inc

Develops nuclear transport modulators for cancer treatment.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

• New hope for myelofibrosis: selinexor trial targets spleen and symptoms Results expected Sep 2026 (estimated) May already have reported ↗
• New hope for lymphoma patients with no other options Results expected Dec 2026 (estimated) May already have reported ↗
• New pill combo aims to tackle tough lymphoma when other treatments fail Results expected Dec 2026 (estimated) 🚀 Make-or-break
• New drug cocktails aim to tackle tough myeloma Results expected Apr 2027 (estimated) May already have reported ↗
• New drug hope for myelofibrosis patients with low platelets Results expected Jun 2027 (estimated) May already have reported ↗